πŸ“š Johnson & Johnson: The Tylenol Recall (1982)

Core Lesson: The gold standard of crisis management β€” J&J chose stakeholder safety over short-term profits, pulled 31 million bottles from shelves, and rebuilt trust to recapture the market. Ethics and business results were aligned.


πŸ“‹ Case Overview

AttributeDetail
CompanyJohnson & Johnson
CEOJames Burke
EventSeven people died in Chicago after taking cyanide-laced Tylenol capsules
DateSeptember–October 1982
Market position pre-crisisTylenol had 35% market share; #1 OTC pain reliever in the US
Market position post-recallRecovered to 35% within one year

πŸ•°οΈ Background

In late September 1982, seven people in the Chicago area died after taking Extra-Strength Tylenol capsules laced with potassium cyanide. It quickly became clear this was product tampering by an unknown third party after the capsules left J&J’s factories β€” but this distinction didn’t matter immediately to a terrified public.

Tylenol was J&J’s best-selling product (17% of company profits). Every business advisor told Burke to stay calm, not to panic, let the investigation conclude. The tampering was clearly external β€” J&J was legally not at fault.


❓ The Decision

The critical fork in the road:

Option A (what advisors recommended): Recall only Chicago-area product. Get ahead of the story with PR. Cooperate with investigation. Minimize financial damage ($100M+ loss from full recall).

Option B (what Burke chose): Nationwide recall of ALL Tylenol capsules. Full cooperation with FDA and FBI. Complete transparency with media. Redesign packaging to triple-seal tamper-evident bottles.

Burke chose Option B β€” citing J&J’s Credo, written by Robert Wood Johnson II in 1943:

β€œWe believe our first responsibility is to patients, doctors, nurses, and all who use our products… Our final responsibility is to our stockholders.”

The Credo explicitly ranked shareholders last.


πŸ“Š The Response β€” What J&J Actually Did

DayJ&J Action
Day 1Alerted nationwide; pulled Chicago ads
Day 2Established crisis hotline for consumers and media
Day 3Ordered nationwide recall β€” 31 million bottles, ~$100M cost
Week 2Worked with FDA to create tamper-evident packaging standards
Week 3CEO James Burke appeared on 60 Minutes, Donahue β€” complete transparency
6 weeks laterRe-introduced Tylenol in new triple-seal tamper-evident packaging
1 year laterTylenol market share recovered to 35%

πŸ“ˆ Outcomes That Stunned Business Experts

Most experts predicted Tylenol as a brand was finished. Instead:

  • Market share recovered to pre-crisis 35% within 12 months
  • J&J’s stock recovered fully within 6 weeks of recall
  • James Burke named one of the greatest CEOs of the 20th century (Fortune)
  • Tamper-evident packaging became federal law for all OTC medicines
  • The case became the MBA gold standard for ethical crisis management

πŸ”‘ Key Lessons

  1. Ethical action and business interests can align β€” Choosing consumers over short-term profits rebuilt trust that generated long-term market share
  2. Credes and values must be operational β€” J&J’s Credo gave Burke a decision framework before the crisis; the values were real, not performative
  3. Transparency in crisis beats message control β€” Hiding information creates worse rumors; J&J’s openness with media set the narrative
  4. Stakeholder trust is an economic asset β€” The $100M recall cost was dwarfed by the brand equity preserved
  5. Speed matters β€” Each day of delay would have compounded consumer fear and media damage

πŸŽ“ Discussion Questions

  1. Burke’s decision involved spending $100M of shareholder money to protect non-shareholder stakeholders. Was this consistent with the shareholder primacy view?
  2. How do you distinguish β€œethics is good business” (aligned interests) from genuine ethical sacrifice (conflicting interests)?
  3. Would J&J’s response strategy work today in the age of social media? What would change?

πŸ”— Connected Concepts


← βš–οΈ Ethics & ESG MOC | πŸ“š Case Studies MOC